Date Added: 08/02/2017

Date Updated: 08/02/2017

Rapid sepsis detection

Specialties: Haematology & blood products - Infectious disease, microbiology & GUM

Technology Type: Diagnostics

Stage of development: Information not available

Stage of EAA: Assessment Complete

Description, patients and keywords:

There is an urgent need for a diagnostic test to enable the rapid identification and diagnosis of sepsis, especially in patients presenting to emergency departments.

The T2Candida test reported good sensitivity and specificity, however, given the low incidence of candida septicaemia, it is unlikely to be cost-effective. HealthPACT noted that the T2Candida test would be efficacious in some immuno-compromised and oncology patients, however, its need in clinical practice is likely to be minimal. No further research on the T2Candida test on behalf of HealthPACT is warranted at this time.

The evidence-base for rapid sepsis tests such as the IRIDICA remains immature. HealthPACT does not support public investment in technologies such as this in clinical practice at this time and recommends that an overview of all sepsis detection technologies be commissioned.

This report is work in progress and should not be used for external distribution without permission from the originating agency. Users should be aware that reports are based on information available at the time of research and often on a limited literature search.